Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 4;2015(8):CD006731.
doi: 10.1002/14651858.CD006731.pub2.

Pharmaceutical policies: effects of financial incentives for prescribers

Arash Rashidian  1 , Amir-Houshang Omidvari, Yasaman Vali, Heidrun Sturm, Andrew D Oxman
Affiliations

Pharmaceutical policies: effects of financial incentives for prescribers

Arash Rashidian et al. Cochrane Database Syst Rev. .

Abstract

Background: The proportion of total healthcare expenditures spent on drugs has continued to grow in countries of all income categories. Policy-makers are under pressure to control pharmaceutical expenditures without adversely affecting quality of care. Financial incentives seeking to influence prescribers' behaviour include budgetary arrangements at primary care and hospital settings (pharmaceutical budget caps or targets), financial rewards for target behaviours or outcomes (pay for performance interventions) and reduced benefit margin for prescribers based on medicine sales and prescriptions (pharmaceutical reimbursement rate reduction policies). This is the first update of the original version of this review.

Objectives: To determine the effects of pharmaceutical policies using financial incentives to influence prescribers' practices on drug use, healthcare utilisation, health outcomes and costs (expenditures).

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (searched 29/01/2015); MEDLINE, Ovid SP (searched 29/01/2015); EMBASE, Ovid SP (searched 29/01/2015); International Network for Rational Use of Drugs (INRUD) Bibliography (searched 29/01/2015); National Health Service (NHS) Economic Evaluation Database (searched 29/01/2015); EconLit - ProQuest (searched 02/02/2015); and Science Citation Index and Social Sciences Citation Index, Institute for Scientific Information (ISI) Web of Knowledge (citation search for included studies searched 10/02/2015). We screened the reference lists of relevant reports and contacted study authors and organisations to identify additional studies.

Selection criteria: We included policies that intend to affect prescribing by means of financial incentives for prescribers. Included in this category are pharmaceutical budget caps or targets, pay for performance and drug reimbursement rate reductions and other financial policies, if they were specifically targeted at prescribing or drug utilisation. Policies in this review were defined as laws, rules, regulations and financial and administrative orders made or implemented by payers such as national or local governments, non-government organisations, private or social insurers and insurance-like organisations. One of the following outcomes had to be reported: drug use, healthcare utilisation, health outcomes or costs. The study had to be a randomised or non-randomised trial, an interrupted time series (ITS) analysis, a repeated measures study or a controlled before-after (CBA) study.

Data collection and analysis: At least two review authors independently assessed eligibility for inclusion of studies and risks of bias using Cochrane Effective Practice and Organisation of Care (EPOC) criteria and extracted data from the included studies. For CBA studies, we reported relative effects (e.g. adjusted relative change). The review team re-analysed all ITS results. When possible, the review team also re-analysed CBA data as ITS data.

Main results: Eighteen evaluations (six new studies) of pharmaceutical policies from six high-income countries met our inclusion criteria. Fourteen studies evaluated pharmaceutical budget policies in the UK (nine studies), two in Germany and Ireland and one each in Sweden and Taiwan. Three studies assessed pay for performance policies in the UK (two) and the Netherlands (one). One study from Taiwan assessed a reimbursement rate reduction policy. ITS analyses had some limitations. All CBA studies had serious limitations. No study from low-income or middle-income countries met the inclusion criteria.Pharmaceutical budgets may lead to a modest reduction in drug use (median relative change -2.8%; low-certainty evidence). We are uncertain of the effects of the policy on drug costs or healthcare utilisation, as the certainty of such evidence has been assessed as very low. Effects of this policy on health outcomes were not reported. Effects of pay for performance policies on drug use and health outcomes are uncertain, as the certainty of such evidence has been assessed as very low. Effects of this policy on drug costs and healthcare utilisation have not been measured. Effects of the reimbursement rate reduction policy on drug use and drug costs are uncertain, as the certainty of such evidence has been assessed as very low. No included study assessed the effects of this policy on healthcare utilisation or health outcomes. Administration costs of the policies were not reported in any of the included studies.

Authors' conclusions: Although financial incentives are considered an important element in strategies to change prescribing patterns, limited evidence of their effects can be found. Effects of policies, including pay for performance policies, in improving quality of care and health outcomes remain uncertain. Because pharmaceutical policies have uncertain effects, and because they might cause harm as well as benefit, proper evaluation of these policies is needed. Future studies should consider the impact of these policies on health outcomes, drug use and overall healthcare expenditures, as well as on drug expenditures.

PubMed Disclaimer

Conflict of interest statement

AR has conducted short consultancies on health financing for the World Health Organization (WHO), Ministries of Health and social health insurance organisations in a few countries that included consideration of pharmaceutical policies. HS was supported by the Dutch Health Care Insurance Board (CVZ).

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Baines 1997c {published data only}
    1. Baines DL, Brigham P, Phillips DR, Tolley KH, Whynes DK. GP fundholding and prescribing in UK general practice: evidence from two rural, English Family health Services Authorities. Public Health 1997;111:321‐5. [4531] - PubMed
Bradlow 1993 {published data only}
    1. Bradlow J, Coulter A. Effect of fundholding and indicative prescribing schemes on general practitioners prescribing cost. BMJ 1993;307(6913):1186‐89. - PMC - PubMed
    1. Stewart‐ Brown S, Surender K. Bradlow J. Coulter A. Doll H. The effects of fundholding in general practice on prescribing habits three years after the introduction of the scheme. BMJ 1995;311:1543‐7. - PMC - PubMed
Burr 1992 {published data only}
    1. Burr AJ, Walker R, Stent SJ. Impact of fundholding on general practice prescribing patterns. The Pharmaceutical Journal 1992;249:R8.
Chou 2008 {published data only}
    1. Chou CC, Hu KY, Wu NR, Cheng YH, Loh CH, Yeh MK. Changes in drug prescription utilization for diabetic and hypertensive outpatients after initiation of the National Health Insurance’s Global Budget Program in Taiwan. Medical Science Monitor 2008;14(5):PH33‐9. - PubMed
Chu 2008 {published data only}
    1. Chu HL, Liu SZ, Romeis JC. Changes in prescribing behaviors after implementing drug reimbursement rate reduction policy in Taiwan: implications for the Medicare system. Journal of Health Care Finance 2008;34(3):45‐54. - PubMed
Corney 1997 {published data only}
    1. Corney RH, Kerrison S. Fundholding in the South Thames region. British Journal of General Practice 1997;47(422):553‐6. - PMC - PubMed
Doran 2011 {published data only}
    1. Doran T, Kontopantelis E, Valderas JM, Campbell S, Roland M, Salisbury C, et al. Effect of financial incentives on incentivised and non‐incentivised clinical activities: longitudinal analysis of data from the UK Quality and Outcomes Framework. British Medical Journal 2011;342:d3590. - PMC - PubMed
Granlund 2006 {published data only}
    1. Granlund D, Rudholm N, Wikström M. Fixed bud gets as a cost containment measure for pharmaceuticals. The European Journal of Health Economics 2006;7(1):35‐45. - PubMed
Guether 1995 {published data only}
    1. Guether B. Effects of German health legislation on the prescriptions of GPs [Auswirkungen des GSG auf das Verordnungsverhalten niedergelassener Aerzte]. Gesundheitswesen 1995;57:185‐91. - PubMed
Harris 1996 {published data only}
    1. Harris CM, Scrivener G. Fundholders' prescribing cost: the first five years. BMJ 1996;313:1531‐4. - PMC - PubMed
Martens 2007 {published data only}
    1. Martens JD, Werkhoven MJ, Severens JL, Winkens RA. Effects of a behaviour independent financial incentive on prescribing behaviour of general practitioners. Journal of Evaluation in Clinical Practice 2007;13(3):369‐73. - PubMed
Rafferty 1997 {published data only}
    1. Rafferty T. Wilson‐ Davis K, McGavock H. How has fundholding in Northern Ireland affected prescribing patterns? A longitudinal study. BMJ 1997;315:166‐70. - PMC - PubMed
Schöffski 1997 {published data only}
    1. Schöffski O. Consequences of implementing a drug budget for office‐based physicians in Germany. Pharmaeconomics 1996;10 Suppl. 2:37‐47. - PubMed
Serumaga 2011 {published data only}
    1. Serumaga B, Ross‐Degnan D, Avery AJ, Elliott RA, Majumdar SR, Zhang F, et al. Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom:interrupted time series study. British Medical Journal 2011;342:d108. - PMC - PubMed
Walley 2000 {published data only}
    1. Walley T, Murphy M, Codd M, Johnston Z, Quirke T. Effects of monetary incentive on primary care prescribing in Ireland: changes in prescribing patterns in one health board 1990‐1995. Pharmacoepidemiology and Drug Safety 2000;9:591‐8. - PubMed
Whynes 1997 {published data only}
    1. Whynes DK, Baines DL, Tolley KH. GP fundholding and the costs of prescribing: further results. Journal of Public Health Medicine 1997;19(1):18‐22. - PubMed
Wilson 1995 {published data only}
    1. Wilson RP, Buchan I, Walley T. Alterations in prescribing by general practitioner fundholders: an observational study. BMJ 1995;311(7016):1347‐50. - PMC - PubMed
    1. Wilson RP, Hatcher J, Barton S, Walley T. General practice fundholders' prescribing savings in one region of the United Kingdom. Health Policy 1997;42:29‐37. - PubMed
    1. Wilson RP, Hatcher J, Barton S, Walley T. Influences of practice characteristics on prescribing in fundholding and non‐fundholding general practices: an observational study. BMJ 1996;313:595‐9. - PMC - PubMed
Wilson 1999 {published data only}
    1. Wilson RPH, Hatcher J, Barton S, Walley T. Therapeutic substitution and therapeutic conservatism as cost‐containment strategies in primary care: a study of fundholders and non‐fundholders. British Journal of General Practice 1999;443:431‐5. - PMC - PubMed

References to studies excluded from this review

Andersson 2009 {published data only}
    1. Andersson K, Carlsten A, Hedenrud T. Prescribing behaviour after the introduction of decentralized drug budgets: is there an association with employer and type of care facility?. Scandinavian Journal of Primary Health Care 2009;27:117‐22. - PMC - PubMed
Ashworth 2004 {published data only}
    1. Ashworth M, Lea R, Gray H, Rowlands G, Gravelle H, Majeed A. How are primary care organizations using financial incentives to influence prescribing?. Journal of Public Health 2004;26(1):48‐51. - PubMed
Bain 1993 {published data only}
    1. Bain J. Budget holding in Calverton: one year on. BMJ 1992;304(6832):971‐3. - PMC - PubMed
    1. Bain J. The New NHS: the second year. Budget holding: here to stay?. BMJ 1993;306(6886):1185‐8. - PMC - PubMed
Baines 1997 {published data only}
    1. Baines DL, Whynes DK, Tolley KH. General practitioner fundholding and prescribing expenditure control. Evidence from a rural English health authority. Pharmacoeconomics 1997;11(4):350‐8. [13861] - PubMed
Baines 1997b {published data only}
    1. Baines DL, Brigham P, Phillips DR, Tolley KH, Whynes DK. GP fundholding and prescribing in UK general practice: evidence from two rural English family health authorities. Public Health 1997;111(5):321‐5. - PubMed
Bateman 1996 {published data only}
    1. Bateman DN, Campbell M, Donaldson LJ, Roberts SJ, Smith JM. A prescribing incentive scheme for non‐fundholding general practices: an observational study. BMJ 1996;313:535‐8. - PMC - PubMed
Bergström 2007 {published data only}
    1. Bergström G, Karlberg I. Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden. Assessment of models for decentralized financing of subsidies from a management perspective. Health Policy 2007;81(2‐3):358‐67. - PubMed
Bhargava 2010 {published data only}
    1. Bhargava V, Greg ME, Shields MC. Addition of generic medication vouchers to a pharmacist academic detailing program: effects on the generic dispensing ratio in a physician‐hospital organization. Journal of Managed Care Pharmacy 2010;16(6):384‐92. - PMC - PubMed
Bhatti 2007 {published data only}
    1. Bhatti TA, Einarson TH, Austin Z, Grootendorst P. The impact of financial incentives on pharmacist dispensing habits: evidence from the British Columbia Product Incentive Plan. Journal of Pharmaceutical Finance, Economics and Policy 2007;16(4):35.
Black 2009 {published data only}
    1. Blak BT, Mullins CD, Shaya FT, Simoni‐Wastila L, Cooke CE, Weir MR. Prescribing trends and drug budget impact of the ARBs in the UK. Value Health 2009;12(2):302‐8. - PubMed
Bryant 2005 {published data only}
    1. Bryant J, Prohmmo A. Payment mechanisms and prescriptions in four Thai hospitals. Health Policy 2005;73(2):160‐71. - PubMed
Campbell 2007 {published data only}
    1. Campbell S, Reeves D, Kontopantelis E, Sibbald B, Roland M. Quality of primary care in England with the introduction of pay for performance. New England Journal of Medicine 2007;357(2):181‐90. - PubMed
Campbell 2009 {published data only}
    1. Campbell S, Reeves D, Kontopantelis E, Sibbald B, Roland M. Effects of pay‐for‐performance on the quality of primary care in England. New England Journal of Medicine 2009;361(4):368‐78. - PubMed
Chang 2009 {published data only}
    1. Chang SL, Liao JC, Shinghal R. Decreasing use of luteinizing hormone‐releasing hormone agonists in the United States is Independent of Reimbursement Changes: a Medicare and Veterans Health Administration claims analysis. Journal of Urology 2009;182:255‐61. - PubMed
Chen 2008 {published data only}
    1. Chen CL, Chen L, Yang WC. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most‐used classes of cardiovascular drugs. BMC Public Health 2008;8:118. [DOI: 10.1186/1471-2458-8-118.] - DOI - PMC - PubMed
Chernew 2000 {published data only}
    1. Chernew M, Cowen ME, Kirking DM, Smith DG, Valenstein P, Fendrick AM. Pharmaceutical cost growth under capitation: a case study. Health Affairs 2000;19(6):266‐76. - PubMed
Chou 2010 {published data only}
    1. Chou SY, Deily ME, Lien HM, Zhang JH. Global budgets and provider incentives: hospitals' drug expenditures in Taiwan. Advances in Health Economics and Health Services Research 2010;22:103‐22. - PubMed
Chu 2008b {published data only}
    1. Chu HL, Liu SZ, Romeis JC. The effects of physicians' financial incentives on the effectiveness of Taiwan's outpatient drug copayment policy. Drug Information Journal 2008;42:493‐502.
Chu 2010 {published data only}
    1. Chu HL, Liu SZ, Romeis JC. Do drug price adjustment policies work? The impact of physician financial incentive plans on the implementation of drug cost containment mechanisms. Drug Information Journal 2010;44:189‐98.
Chung 2010a {published data only}
    1. Chung S, Palaniappan LP, Trujillo LM, Rubin HR, Luft HS. Effect of physician‐specific pay‐for‐performance incentives in a large group practice. The American Journal of Managed Care 2010;16(2):e35‐42. - PubMed
Chung 2010b {published data only}
    1. Chung S, Palaniappan L, Wong E, Rubin H, Luft H. Does the frequency of pay‐for‐performance payment matter? Experience from a randomized trial. Health Services Research 2010;45(2):553‐64. - PMC - PubMed
Coulter 1993 {published data only}
    1. Coulter A, Bradlow J. Effect of NHS reforms on general practitioners' referral patterns. BMJ 1993;306:433‐7. - PMC - PubMed
    1. Surender R. Prospective study of trends in referral patterns in fundholding and non‐fundholding practices in the Oxford region, 1990‐4. BMJ 1995;311:1205‐8. - PMC - PubMed
Curttis 2003 {published data only}
    1. Curtiss FR. Effects of physician report cards, knowledge of drug prices, and financial incentives in prescription drug costs. Journal of Managed Care Pharmacy 2003;9(4):368‐71. - PMC - PubMed
Danzon 1997 {published data only}
    1. Danzon PM, Liu H. Reference pricing and physician drug budgets: the German experience in controlling pharmaceutical expenditures. Philadelphia, PA: Wharton School Working Paper, University of Philadelphia, 1997.
Delmar 2006 {published data only}
    1. Delmar C. Improving prescribing practices in primary care. A randomised trial and economic analysis of a multicomponent intervention showed small, but important, gains. PLoS Medicine 2006;3(6):e229. - PMC - PubMed
Doshi 2010 {published data only}
    1. Doshi JA, Li P, Puig A. Impact of the Medicare Modernization Act of 2003 on utilization and spending for Medicare part B‐covered biologics in rheumatoid arthritis. Arthritis Care Research (Hoboken) 2010;62(3):354‐61. - PMC - PubMed
Dusheiko 2003 {published data only}
    1. Dusheiko M, Gravelle H, Jacobs R, Smith PC. The effects of budgets on doctor behaviour: evidence from a natural experiment. York, UK: University of York Discussion Paper,. York, UK: University of York, 2003.
Edgar 1999 {published data only}
    1. Edgar S, Girvin B. Effects of hospital‐led prescribing on the cardiovascular budget of a fundholding general practice. The Pharmaceutical Journal 1999;263:292‐4.
Elhayany 2001 {published data only}
    1. Elhayany A, Regev S, Sherf M, Reuveni H, Shvartzman P. Effects of a fundholding discontinuation. An Israeli Health Maintenance Organization Natural Experiment 2001;19:223‐6. - PubMed
Elliott 2010 {published data only}
    1. Elliott SP, Jarosek SL, Wilt TJ, Virnig BA. Reduction in physician reimbursement and use of hormone therapy in prostate cancer. Journal of the National Cancer Institute 2010;102(24):1826‐34. - PMC - PubMed
Etter 1998 {published data only}
    1. Etter J‐F, Perneger TV. Health care expenditures after introduction of a gatekeeper and a global budget in a Swiss health insurance plan. Journal of Epidemiology and Community Health 1997;52(6):370‐4. - PMC - PubMed
Fear 1994 {published data only}
    1. Fear CF, Cattell HR. Fund‐holding general practices and old age psychiatry. Psychiatric Bulletin 1994;18:263‐5.
Hespanhol 2005 {published data only}
    1. Hespanhol A, Sousa Pinto A. The payment model in Sao Joao Health Center ‐ "Tubo de Ensaio". Arquivos De Medicina 2005;19(3):113‐20.
Hoffman 2010 {published data only}
    1. Hoffmann F, Windt R, Glaeske G. Implementation of "aut idem" before and after introduction of rebate contracts [Umsetzung der Aut‐idem‐Regelung vor und nachEinführung der Rabattverträge]. Deutsch Medizinische Wochenschrift 2010;135:739‐44. - PubMed
Hoopmann 1995 {published data only}
    1. Hoopmann M, Schwartz FW, Weber J. Effects of the German 1993 health reform law upon primary care practitioners individual performance: results form an empirical study in sentinel practices. Journal of Epidemiology and Community Health 1995;49:33‐6. - PMC - PubMed
Houghton 1998 {published data only}
    1. Houghton G, Gilthorpe MS. Variations in general practice prescribing: a multilevel model approach to determine the impact of characteristics, including fundholding and training status. Journal of Clinical Effectiveness 1998;3(2):75‐9.
Howie 1995 {published data only}
    1. Howie JGR, Heaney DJ, Maxwell M. General practice fund‐holding: shadow project ‐ an evaluation. Edinburgh, Scotland: The Department of General Practice, University of Edinburgh,. Edinburgh: The Department of General Practice, University of Edinburgh, 1995.
Jacobson 2006 {published data only}
    1. Jacobson M, O'Malley AJ, Earle CC, Pakes J, Gaccione P, Newhouse JP. Does reimbursement influence chemotherapy treatment for cancer patients?. Health Affairs 2006;25(2):437‐43. - PubMed
Jünger 2000 {published data only}
    1. Jünger C, Rathmann W, Giani G. Prescribing practices of general practitioners and internists in the treatment of diabetic patients: influence of drug budgeting [Primaeraerztliches Verordnungsverhalten bei der Diabetestherapie: Einfluss der Arzneimittelbudgetierung]. Deutsch Medizinische Wochenschrift 2000;125:103‐9. - PubMed
    1. Jünger C, Rathmann W, Giani G. Prescription drug use of primary care physicians in Germany among diabetic and nondiabetic patients [Primaeraerztliche Arzneimittelverordnungen bei Diabetikern und Nichtdiabetikern: Einfluss der Arzneimittelbudgetierung]. Gesundheitswesen 1999;61:607‐13. - PubMed
Kaestner 2012 {published data only}
    1. Kaestner R, Khan N. Medicare Part D and its effect on the use of prescription drugs and use of other health care services of the elderly. Journal of Policy Analysis and Management 2012;31(2):253‐79.
Kammerling 1996 {published data only}
    1. Kammerling R. Kinnear A. The extent of the two tier service for fundholders. BMJ 1996;312:1399‐401. - PMC - PubMed
Landon 2007 {published data only}
    1. Landon BE, Rosenthal MB, Normand SL, Spettell C, Lessler A, Underwood HR, et al. Incentive formularies and changes in prescription drug spending. American Journal of Managed Care 2007;13(6 Pt 2):360‐9. - PubMed
Lee 2007 {published data only}
    1. Lee YC, Huang KH, Huang YT. Adverse pharmaceutical payment incentives and providers' behaviour: the emergence of GP‐owned gateway pharmacies in Taiwan. Health Policy and Planing 2007;22(6):427‐35. - PubMed
Li 2008 {published data only}
    1. Li L, Chen Y, Yao L, Li Y. Evaluation of the effects of implementing the policy "Without Added Profit" to sale drug in community health service institutions of Chengdu. Chinese Journal of New Drugs 2008;17(21):1820‐2.
Ling 2008 {published data only}
    1. Ling DC, Berndt ER, Frank RG. Economic incentives and contracts: the use of psychotropic medications. Contemporary Economic Policy 2008;1:49‐72.
Liu 2009 {published data only}
    1. Liu YM, Yang YH, Hsieh CR. Financial incentives and physicians' prescription decisions on the choice between brand‐name and generic drugs: evidence from Taiwan. Journal of Health Economics 2009;28(2):341‐9. - PubMed
Malcolm 1999 {published data only}
    1. Malcolm L, Wright L, Seers M, Guthrie J. An evaluation of pharmaceutical management and budget holding in Pegasus Medical Group. New Zealand Medical Journal 1999;112(1087):162‐4. - PubMed
Malcolm 2001 {published data only}
    1. Malcolm L, Barry M, MacLean I. Pharmaceutical management in ProCare Health Limited. New Zealand Medical Journal 2001;114(1134):283‐6. - PubMed
Maxwell 1993 {published data only}
    1. Howie JGR, Heaney DJ, Maxwell M. General practice fund‐holding: shadow project ‐ an evaluation. Edinburgh, Scotland: The Department of General Practice, University of Edinburgh, 1995.
    1. Maxwell M, Heaney D, Howie JGR, Noble S. General practice fundholding: observations on prescribing patterns and cost using the defined daily dose method. BMJ 1993;307(6913):1190‐4. - PMC - PubMed
Maynard 2010 {published data only}
    1. Maynard A, Bloor K. Will financial incentives and penalties improve hospital care?. British Medical Journal 2010;340:c88. - PubMed
Millet 2007 {published data only}
    1. Millett C, Gray J, Saxena S, Netuveli G, Khunti K, Majeed A. Ethnic disparities in diabetes management and pay‐for‐performance in the UK: the Wandsworth Prospective Diabetes Study. PLOS Medicine 2007;4(6):191. - PMC - PubMed
Mossalios 2005 {published data only}
    1. Mossialos E, Walley T, Rudisill C. Provider incentives and prescribing behavior in Europe. Expert Review on Pharmacoeconomics and Outcomes Research 2005;5(1):81‐93. - PubMed
Newton 1993 {published data only}
    1. Newton J, Fraser M, Robinson J, Wainwright D. Fundholding in the northern region: the first year. BMJ 1993;306:375‐8. - PMC - PubMed
O'Malley 2006 {published data only}
    1. O'Malley AJ, Frank RG, Kaddis A, Rothenberg BM, McNeil BJ. Impact of alternative interventions on changes in generic dispensing rates. Health Services Research 2006;41(5):1876‐94. - PMC - PubMed
Ohlsson 2007 {published data only}
    1. Ohlsson H, Merlo J. Understanding the effects of a decentralized budget on physicians' compliance with guidelines for statin prescription – a multilevel methodological approach. BMC Health Services Research 2007;7:68. - PMC - PubMed
Peabody 2011 {published data only}
    1. Peabody J, Shimkhada R, Quimbo S, Florentino J, Bacate M, McCulloch CE, et al. Financial incentives and measurement improved physicians' quality of care in the Philippines. Health Affairs (Millwood) 2011;30(6):1217. - PubMed
Prokes 2009 {published data only}
    1. Prokes M, Suchopar J. Effect of drug budgets on drug prescription in Czech Republic in 2006. Klinicka Farmakologie a Farmacie 2009;23(2):90‐6.
Sakshaug 2007 {published data only}
    1. Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S. Switching statins in Norway after new reimbursement policy – a nationwide prescription study. British Journal of Clinical Pharmacology 2007;64(4):476‐81. - PMC - PubMed
Schmidt 2006 {published data only}
    1. Schmidt K. Incentives for especially cost effective prescribing. The physician protects his budget, the patient saves co‐pay. MMW Fortschritte dir medizin 2006;148(44):57‐9. - PubMed
Schreyögg 2004 {unpublished data only}
    1. Schreyögg J. Physician Prescribing Budgets in Germany: Effects on Prescribing Behaviour. Berlin, Germany: Department of Health Care Management, Faculty of Economics and Management, Berlin University of Technology, 2005.
Schreyögg 2005 {published data only}
    1. Schreyögg J, Busse R. Physician drug budgets in Germany: effects on prescription behaviour. Journal of Pharmaceutical Finance 2005;14(3):77‐95.
Trifirio 2008 {published data only}
    1. Trifirò G, Alacqua M, Corrao S, Moretti S, Tari DU, Galdo M, et al. UVEC Group. Lipid‐lowering drug use in Italian primary care: effects of reimbursement criteria revision. European Journal of Clinical Pharmacology 2008;64(6):619‐25. - PubMed
Whynes 1995 {published data only}
    1. Whynes DK, Baines DL, Tolley KH. GP fundholding and the cost of prescribing. Journal of Public Health Medicine 1995;17:323‐9. - PubMed
Whynes 1997b {published data only}
    1. Wilson RP, Hatcher J, Barton S, Walley T. General practice fundholders' prescribing savings in one region of the United Kingdom, 1991‐1994. Health Policy 1997;42:29‐37. - PubMed
Zhang 2012 {published data only}
    1. Zhang Y, Baik SH, Zhou L, Reynolds CF, Lave JR. Effects of Medicare Part D coverage gap on medication and medical treatment among elderly beneficiaries with depression. Archives of General Psychiatry 2012;69(7):672‐9. - PMC - PubMed

References to studies awaiting assessment

Chang 2013 {published data only}
    1. Chang J, Freed GL, Prosser LA, Patel I, Erickson SR, Bagozzi RP, Balkrishnan R. Associations between physician financial incentives and the prescribing of anti‐asthmatic medications in children in US outpatient settings. Journal of Child Health Care. 2013;17(2):125‐37. - PubMed
Harrison 2014 {published data only}
    1. Harrison MJ, Dusheiko M, Sutton M, Gravelle H, Doran T, Roland M. Effect of a national primary care pay for performance scheme on emergency hospital admissions for ambulatory care sensitive conditions: controlled longitudinal study. BMJ. 2014;349:g6423. - PMC - PubMed
Kontopantelis 2013 {published data only}
    1. Kontopantelis E, Reeves D, Valderas JM, Campbell S, Doran T. Recorded quality of primary care for patients with diabetes in England before and after the introduction of a financial incentive scheme: a longitudinal observational study. BMJ Quality and Safety 2013;22(1):53‐64. - PubMed
Kristensen 2014 {published data only}
    1. Kristensen SR, Meacock R, Turner AJ, Boaden R, McDonald R, Roland M, et al. Long‐term effect of hospital pay for performance on mortality in England. New England Journal of Medicine 2014;371(6):540‐8. - PubMed
Li 2014 {published data only}
    1. Li J, Hurley J, DeCicca P, Buckley G. Physician response to pay‐for‐performance: evidence from a natural experiment. Health Economics 2014;23(8):962‐78. - PubMed
MacBride‐Stewart 2008 {published data only}
    1. MacBride‐Stewart SP, Elton R, Walley T. Do quality incentives change prescribing patterns in primary care? An observational study in Scotland. Family Practice 2008;25(1):27‐32. - PubMed
Naomh Gallagher 2012 {published data only}
    1. Naomh Gallagher N. Type 2 diabetes and cardiovascular drug therapy on the island of Ireland: do financial incentives change prescribing behaviour?. European Journal of Preventive Cardiology 2012;1:S20.
Park 2014 {published data only}
    1. Park S, et al. Differential effects of two pharmaceutical cost containment policies on outpatient prescription drug expenditures in Korea. Value in Health 2014;17(3):A14.
Sun 2014 {published data only}
    1. Sun X, Liu X, Sun Q, Yip W, Wagstaff A, Meng Q. The impact of a pay‐for‐performance scheme on prescription quality in rural China: an impact evaluation. Policy Research Working Paper Series 2014;6892:No 750.
Zhang 2014 {published data only}
    1. Zhang JH, Chou SY, Deily ME, Lien HM. Hospital ownership and drug utilization under a global budget: a quantile regression analysis. International Health 2014;6(1):62‐9. - PubMed

Additional references

Aaserud 2006a
    1. Aaserud M, Dahlgren AT, Sturm H, Koesters JP, Hill S, Furberg CD, et al. Pharmaceutical policies: effects on rational drug use. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004397.pub2] - DOI
Acosta 2014
    1. Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll‐Dahlgren A, Kösters JP, et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD005979.pub2] - DOI - PMC - PubMed
Antonanzas 2003
    1. Antonanzas F. Challenges to achieving value in drug spending in a decentralized country: the Spanish case. Value in Health 2003;6:52‐63. - PubMed
Armour 2001
    1. Armour BS, Pitts MM, Maclean R, Cangialose C, Kishel M, Imai H, Etchason J. The effect of explicit financial incentives on physician behavior. Archives of Internal Medicine 2001;161(10):1261‐6. - PubMed
Atella 2000
    1. Atella V. Drug cost containment policies in Italy: are they really effective in the long‐run? The case of minimum reference price. Health Policy 2000;50(3):197‐218. - PubMed
Audit Comm. 1996
    1. Audit Commission. What the Doctor Ordered: A Study of GP Fundholders in England and Wales. London: HMSO, 1996.
Austvoll‐Dahlgren 2008
    1. Austvoll‐Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, et al. Pharmaceutical policies: effects of cap and co‐payment on rational drug use. Cochrane Database of Systematic Reviews 2008;CD007017:doi: 10.1002/14651858.CD007017. - PubMed
Baines 1996
    1. Baines DL, Whynes DK. Selection bias in GP fundholding. Health Economics 1996;5:129‐40. - PubMed
Bigdeli 2013
    1. Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, et al. Access to medicines from a health system perspective. Health Policy Plan 2013;28(7):692‐704. doi:10.1093/heapol/czs108. - PMC - PubMed
Bloor 1996
    1. Bloor K, Freemantle N. Fortnightly review: lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors. BMJ 1996;312(7045):1525‐7. - PMC - PubMed
Busse 1996
    1. Busse R, Howorth C. Fixed budgets in the pharmaceutical sector in Germany: effects on costs and quality. In: Schwartz FW, Glennerster H, Saltman RB, Busse R editor(s). Fixing Health Budgets: Experience from Europe and North America. New York: John Wiley and Sons, 1996:93‐108.
Calltorp 1996
    1. Calltorp J. Swedish experience with regional budgets. Fixing Health Budgets. New York: John Wiley and Sons, 1996:155‐64.
Calltorp 1999
    1. Calltorp J. Priority setting in health policy in Sweden and a comparison with Norway. Health Policy 1999;50:1‐22. - PubMed
Campbell 2013
    1. Campbell D, Chui M. Pharmerging Shake‐up: New Imperatives in a Re‐defined World. Norwalk, CT: IMS Health, 2013.
Chaix‐Couturier 2000
    1. Chaix‐Couturier C, Durand‐Zaleski I, Jolly D, Durieux P. Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues. International Journal of Quality Health Care 2000;12(2):133‐42. - PubMed
Conrad 2004
    1. Conrad DA, Christianson JB. Penetrating the "black box": financial incentives for enhancing the quality of physician services. Medical Care Research and Review 2004;61(3):37‐68. - PubMed
Coulter 1995
    1. Coulter A. Evaluating general practice fundholding in the United Kingdom. European Journal of Public Health 1995;5:233‐9.
Croxson 2001
    1. Croxson B, Propper C, Perkins A. Do doctors respond to financial incentives? UK family doctors and the GP fundholder scheme. Journal of Public Economics 2001;79:375‐98.
Day 1991
    1. Day P, Klein R. Variations in budgets of fundholding practices. BMJ 1991;303(6795):168‐70. - PMC - PubMed
Delnoij 2000
    1. Delnoij D, Brenner G. Importing budget systems from other countries: what can we learn from the German drug budget and the British GP fundholding?. Health Policy 2000;52(3):157‐69. - PubMed
Doloresco 2011
    1. Doloresco F, Fominaya C, Schumock GT, Vermeulen LC, Matusiak L, Hunkler RJ, et al. Projecting future drug expenditures: 2011. American Journal of Health‐System Pharmacy 2011;68(10):921‐32. - PubMed
Eichler 2009
    1. Eichler R, Levine R. Performance Incentives for Global Health: Potential and Pitfalls. Washington, DC: Center for Global Development, 2009.
Eijkenaar 2013
    1. Eijkenaar F, Emmert M, Scheppach M, Schoffski O. Effects of pay for performance in health care: a systematic review of systematic reviews. Health Policy 2013;110:115‐30. - PubMed
Emmerick 2013
    1. Emmerick IC, Oliveira MA, Luiza VL, Azeredo TB, Bigdeli M. Access to medicines in Latin America and the Caribbean (LAC): a scoping study. BMJ Open 2013;3(5):pii: e002224. doi: 10.1136/bmjopen‐2012‐002224.. - PMC - PubMed
EPOC 2013a
    1. Effective Practice, Organisation of Care (EPOC). What study designs should be included in an EPOC review and what should they be called?. EPOC Resources for Review Authors. Oslo: Norwegian Knowledge Centre for the Health Services 2013. Available at: http://epocoslo.cochrane.org/epoc‐specific‐resources‐review‐authors.
EPOC 2013b
    1. Effective Practice, Organisation of Care (EPOC). What outcomes should be reported in EPOC reviews?. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services 2013. Available at: http://epocoslo.cochrane.org/epoc‐specific‐resources‐review‐authors.
EPOC 2013c
    1. Effective Practice, Organisation of Care (EPOC). Interrupted time series (ITS) analyses. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services 2013. Available at: http://epocoslo.cochrane.org/epoc‐specific‐resources‐review‐authors.
EPOC 2013d
    1. Effective Practice, Organisation of Care (EPOC). EPOC worksheets for preparing a Summary of Findings (SoF) table using GRADE. EPOC Resources for Review Authors. Oslo: Norwegian Knowledge Centre for the Health Services 2013. Available at: http://epocoslo.cochrane.org/epoc‐specific‐resources‐review‐authors.
EPOC 2015
    1. Effective Practice, Organisation of Care (EPOC). Suggested risk of bias criteria for EPOC reviews. EPOC Resources for review authors. Oslo: Norwegian Knowledge Centre for the Health Services 2015. Available at: http://epocoslo.cochrane.org/epoc‐specific‐resources‐review‐authors.
Ess 2003
    1. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003;21(2):89‐103. - PubMed
Fattore 1998
    1. Fattore G, Jommi C. The new pharmaceutical policy in Italy. Health Policy 1998;46(1):21‐41. - PubMed
Feely 1999
    1. Feely J. The therapeutic gap ‐ compliance with medication and guidelines. Atherosclerosis 1999;147(Suppl 1):31‐7. - PubMed
Garrison 2003
    1. Garrison L, Towse A. The drug budget silo mentality in Europe: an overview. Value in Health 2003;6:1‐9. - PubMed
Giuffrida 2000
    1. Giuffrida A, Gosden T, Forland F, Kristiansen IS, Sergison M, Leese B, et al. Target payments in primary care: effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD000531] - DOI - PMC - PubMed
Glynn 1992
    1. Glynn J, Murphy M, Perkins D. GP practice budgets: an evaluation of the financial risks and rewards. Financial Accountability and Management 1992;8:149‐61.
Gosden 1997
    1. Gosden T, Torgerson DJ. The effect of fundholding on prescribing and referral costs: a review of the evidence. Health Policy 1997;40(2):103‐14. - PubMed
Gosden 2001
    1. Gosden T, Forland F, Kristiansen IS, Sutton M, Leese B, Giuffrida A, et al. Impact of payment method on behaviour of primary care physicians: a systematic review. Health Services Research and Policy 2001;6(1):44‐55. - PubMed
GRADE 2004
    1. The GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490‐4. - PMC - PubMed
Griffin 1996
    1. Griffin JP. An historical survey of UK government measures to control the NHS medicines expenditure from 1948 to 1996. Pharmacoeconomics 1996;10(3):210‐24. - PubMed
Gross 1994
    1. Gross DJ, Ratner J, Perez J, Glavin SL. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom. Health Care Financing Review 1994;15(3):127‐40. - PMC - PubMed
Harrison 1996
    1. Harrison S, Choudhry N. General practice fundholding in the UK National Health Service: evidence to date. Journal of Public Health Policy 1996;17(3):331‐46. - PubMed
Healey 1994
    1. Healey AT. Do prospective fundholders inflate their prescribing costs? A study of the Grampian fundholding and non‐fundholding practices. Health Bulletin 1994;52(4):282‐4.
Klein 2004
    1. Klein R. Britain's National Health Service revisited. New England Journal of Medicine 2004;350(9):937‐42. - PubMed
Lopez Bastida 2000
    1. Lopez Bastida J, Mossialos E. Pharmaceutical expenditure in Spain: cost and control. International Journal of Health Services 2000;30(3):597‐616. - PubMed
Lu 2008
    1. Lu CY, Ross‐Degnan D, Soumerai SB, Pearson SA. Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature ‐ 2001‐2007. BMC Health Services Research 2008;8(75):doi:10.1186/1472‐6963‐8‐75. - PMC - PubMed
Lu 2011
    1. Lu Y, Hernandez P, Abegunde D, Edejer T. The world medicines situation 2011; medicine expenditure. WHO/EMP/MIE 2011; Vol. 2.6.
Lundkvist 2002
    1. Lundkvist J. Pricing and reimbursement of drugs in Sweden. European Journal of Health Economics 2002;3(1):66‐70. - PubMed
Mannion 2005
    1. Mannion R. Practice based commissioning: a summary of the evidence. Health Policy 2005;11:1‐4.
Mapelli 2003
    1. Mapelli V, Lucioni C. Spending on pharmaceuticals in Italy: macro constraints with local autonomy. Value in Health 2003;6:31‐45. - PubMed
Maynard 2003
    1. Maynard A, Bloor K. Dilemmas In regulation of the market for pharmaceuticals. Health Affairs 2003;22(3):31‐41. - PubMed
McNamara 2005
    1. McNamara P. Quality‐based payment: six case examples. International Journal of Quality Health Care 2005;17(4):357‐62. - PubMed
Moon 2002
    1. Moon G, Mohan J, Twigg L, McGrath K, Pollock A. Catching waves: the historical geography of the general practice fundholding initiative in England and Wales. Social Sciences Medicine 2002;55(12):2201‐13. - PubMed
Mossialos 2004
    1. Mossialos E, Mrazek M, Walley T. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality. Buckingham, Open University Press, 2004.
Mossialos 2005
    1. Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. International Journal of Health Planning and Management 2004;20:291‐306. - PubMed
Narine 1997
    1. Narine L, Senathirajah M. Pharmaceutical Cost Containment Policies: Intended and Unintended Impacts. Toronto, Ontario: University of Toronto Department of Health Administration Report 1997:68‐74.
Okunade 2006
    1. Okunade AA, Suraratdecha C. The pervasiveness of pharmaceutical expenditure inertia in the OECD countries. Social Sciences Medicine 2006;63(1):225‐38. - PubMed
Ostini 2009
    1. Ostini R, Hegney D, Jackson C, Williamson M, Mackson JM, Gurman K, et al. Systematic review of interventions to improve prescribing. Annals of Pharmacotherapy 2009;43(3):502‐13. - PubMed
Oxman 2009
    1. Oxman AD, Fretheim A. Can paying for results help to achieve the Millennium Development Goals? Overview of the effectiveness of results‐based financing. Journal of Evidence‐Based Medicine 2009;2:70‐83. - PubMed
Painter 2005
    1. Painter MR. Reimbursement issues with hormonal therapies for prostate cancer. Reviews on Urology 2005;7 Suppl 5:S44‐7. - PMC - PubMed
Ramsay 2003
    1. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series design in health technology assessment: lessons from two systematic reviews of behavior change strategies. International Journal of Technology Assessment in Health Care 2003;19(4):612‐23. - PubMed
Rashidian 2008
    1. Rashidian A. Falling on stony ground? A qualitative study of implementation of clinical guidelines' prescribing recommendations in primary care. Health Policy 2008;85(2):148‐61. - PubMed
Rashidian 2013
    1. Rashidian A, Jahanmehr N, Jabbour S, Zaidi S, Soleymani F, Bigdeli M. Bibliographic analysis of research publications on access to and use of medicines in low‐income and middle‐income countries in the Eastern Mediterranean Region: identifying the research gaps. BMJ Open 2013;3(10):e003332. doi: 10.1136/bmjopen‐2013‐003332. - PMC - PubMed
Reinhardt 2002
    1. Reinhardt U, Hussey P, Anderson G. Cross‐national comparisons of health systems using OECD data. Health Affairs 2002;21(3):169‐81. - PubMed
Rietveld 2002
    1. Rietveld AdH, Haaijer‐Ruskamp FM. Policy options for cost containment of pharmaceuticals. International Journal of Risk & Safety in Medicine 2002;15:29‐54.
Roland 2004
    1. Roland M. Linking physicians' pay to the quality of care ‐ a major experiment in the United Kingdom. New England Journal of Medicine 2004;351(14):1448‐54. - PubMed
Rosenthal 2004
    1. Rosenthal M, Fernandopulle R, Song H, Landon B. Paying for quality: providers' incentives for quality improvement. Health Affairs 2004;23(2):127‐41. - PubMed
Rosenthal 2006
    1. Rosenthal MB, Landon BE, Normand SL, Frank RG, Epstein AM. Pay for performance in commercial HMOs. New England Journal of Medicine 2006;355:1895‐902. - PubMed
Rowe 2006
    1. Rowe JW. Pay‐for‐performance and accountability: related themes in improving health care. Annals of Internal Medicine 2006;145:695‐9. - PubMed
Sarayani 2014
    1. Sarayani A, Rashidian A, Gholami K. Low utilisation of diabetes medicines in Iran, despite their affordability (2000–2012): a time‐series and benchmarking study. BMJ Open 2014;4:e005859 doi:10.1136/bmjopen‐2014‐005859. - PMC - PubMed
Schwartz 1996
    1. Schwartz FW, Busse R. Fixed budgets in the ambulatory care sector: the German experience. Fixing Health Budgets: Experience from Europe and North America. New York: John Wiley & Sons, 1996:93‐108.
Schwermann 2003
    1. Schwermann T, Greiner W, Schulenburg JM. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany. Value in Health 2003;6 Suppl:S20‐S30. - PubMed
Smith 1998
    1. Smith RD, Wilton P. General practice fundholding: progress to date. Britiah Journal of General Practice 1998;48(430):1253‐7. - PMC - PubMed
Soumerai 1993
    1. Soumerai SB, Avorn J, Taylor WC, Wessels M, Maher D, Hawley SL. Improving choice of prescribed antibiotics through concurrent reminders in an educational order form. Medical Care 1993;31(6):552‐8. - PubMed
Steinbrook 2007
    1. Steinbrook R. Closing the affordability gap for drugs in low‐income countries. New England Journal of Medicine 2007;357(20):1996‐9. - PubMed
Stewart‐Brown 1995
    1. Stewart‐Brown S, Surender R, Bradlow J, Coulter A, Doll H. The effects of fundholding in general practice on prescribing habits three years after introduction of the scheme. BMJ 1995;311:1543‐7. - PMC - PubMed
Sturm 2005
    1. Sturm HB, Gilst WH, Swedberg K, Hobbs FD, Haaijer‐Ruskamp FM. Heart failure guidelines and prescribing in primary care across Europe. BMC Health Services Research 2005;5:57. - PMC - PubMed
Takian 2011
    1. Takian A, Rashidian A, Kabir MJ. Expediency and coincidence in re‐engineering a health system: an interpretive approach to formation of family medicine in Iran. Health Policy Plan 2011;26(2):163‐73. - PubMed
Trude 2006
    1. Trude S, Au M, Christianson JB. Health plan pay for performance strategies. American Journal of Managed Care 2006;12:537‐42. - PubMed
Van Herck 2010
    1. Herck P, Smedt D, Annemans L, Remmen R, Rosenthal MB, Sermeus W. Systematic review: effects, design choices, and context of pay‐for‐performance in health care. BMC Health Services Research 2010;10:247 doi:10.1186/1472‐6963‐10‐247. - PMC - PubMed
Walley 1995
    1. Walley T, Wilson R, Bligh J. Current prescribing in primary care in the UK. Effects of the indicative prescribing scheme and GP fundholding. Pharmacoeconomics 1995;7(4):320‐31. - PubMed
Walley 2004
    1. Walley T, Mossialos E. Financial incentives and prescribing. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality. Buckinghamshire, UK: Open University Press, 2004:177‐95.
Walley 2005
    1. Walley T, Mrazek M, Mossialos E. Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK. International Journal of Health Planning and Management 2005;20(4):375‐98. [DOI: 10.1002/hpm.820] - DOI - PubMed
Weiner 1990
    1. Weiner J, Ferriss D. GP Budget Holding in the UK: Lessons from America. London, UK: King's Fund, 1990.
Wilton 1998
    1. Wilton P, Smith RD. Primary care reform: a three country comparison of 'budget holding'. Health Policy 1998;44(2):149‐66. - PubMed
Witter 2012
    1. Witter S, Fretheim A, Kessy FL, Lindahl AK. Paying for performance to improve the delivery of health interventions in low‐ and middle‐income countries. Cochrane Database of Systematic Reviews 2012;Issue 2:Art. No.:CD007899. DOI: 10.1002/14651858.CD007899.pub2. - PubMed
Zaidi 2013
    1. Zaidi S, Bigdeli M, Aleem N, Rashidian A. Access to essential medicines in Pakistan: policy and health systems research concerns. PLoS One 2013;8(5):e63515. doi: 10.1371/journal.pone.0063515. - PMC - PubMed

References to other published versions of this review

Sturm 2007
    1. Sturm H, Austvoll‐Dahlgren A, Aaserud M, Oxman AD, Ramsay C, Vernby A, et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006731] - DOI - PubMed

Publication types

LinkOut - more resources